PIPE-505
PTI-505-101
Phase 2 small_molecule completed
Quick answer
PIPE-505 for Sensorineural Hearing Loss is a Phase 2 program (small_molecule) at Contineum Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Contineum Therapeutics
- Indication
- Sensorineural Hearing Loss
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed